Scholarlink

<p>The assay of plasma biomarkers plays a role in the assessment of Alzheimer’s disease (AD) and the monitoring of treatments. One of the ultra-sensitive assay technologies is the so-called immunomagnetic reduction (IMR). According to published papers, plasma amyloid β<sub>1-42</sub> peptide (Aβ<sub>1-42</sub>) and total tau protein (T-Tau) are crucial biomarkers. From a practical point of view, it is necessary to monitor the longitudinal assay results in individuals frequently. Hence, it is essential to investigate the time-course measured concentrations of Aβ<sub>1-42</sub> and T-Tau in control samples using IMR. In this work, the time-course measured concentrations of the control samples (Aβ<sub>1-42</sub>: 20&#xa0;pg/ml; T-Tau: 50&#xa0;pg/ml) in IMR from 2016 to 2024 are analyzed. In addition to control samples, the reported levels of Aβ<sub>1-42</sub> and T-Tau in human plasma from 2016 to 2024 assayed with IMR in cognitively normal subjects are inspected. The results show that the slopes of the year-dependent measured concentrations of Aβ<sub>1-42</sub> and T-Tau in control samples over the 8&#xa0;years do not significantly deviate from zero (<i>p</i> &gt; 0.05). The insignificant drift in the reported Aβ<sub>1-42</sub> and T-Tau concentrations in human plasma over the 8&#xa0;years is also found (<i>p</i> &gt; 0.05). These results reveal high consistencies in measured Aβ<sub>1-42</sub> and T-Tau concentrations from time to time using IMR.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Eight-Year Longitudinal Study on the Assay Stability of Plasma Amyloid Beta 1–42 Peptide and Total Tau Protein Using Immunomagnetic Reduction

  • 期刊论文

  • 发表日期：

    2025年5月17日

查看全文
  • Mengyao Ji,
  • Mujun Jiang,
  • Qun Yu,
  • Xiaoyun Huang,
  • Yihong Huang,
  • Jun Liu,
  • Wang Liao

摘要

The assay of plasma biomarkers plays a role in the assessment of Alzheimer’s disease (AD) and the monitoring of treatments. One of the ultra-sensitive assay technologies is the so-called immunomagnetic reduction (IMR). According to published papers, plasma amyloid β1-42 peptide (Aβ1-42) and total tau protein (T-Tau) are crucial biomarkers. From a practical point of view, it is necessary to monitor the longitudinal assay results in individuals frequently. Hence, it is essential to investigate the time-course measured concentrations of Aβ1-42 and T-Tau in control samples using IMR. In this work, the time-course measured concentrations of the control samples (Aβ1-42: 20 pg/ml; T-Tau: 50 pg/ml) in IMR from 2016 to 2024 are analyzed. In addition to control samples, the reported levels of Aβ1-42 and T-Tau in human plasma from 2016 to 2024 assayed with IMR in cognitively normal subjects are inspected. The results show that the slopes of the year-dependent measured concentrations of Aβ1-42 and T-Tau in control samples over the 8 years do not significantly deviate from zero (p > 0.05). The insignificant drift in the reported Aβ1-42 and T-Tau concentrations in human plasma over the 8 years is also found (p > 0.05). These results reveal high consistencies in measured Aβ1-42 and T-Tau concentrations from time to time using IMR.